Abstract:Abstract Background Ovarian serous cystadenocarcinoma (OSC) is the most common pathological subtype of ovarian cancer (OC) associated with high mortality. Albeit dysregulated mitochondrial metabolism has been implicated with OC, the role of mitochondrial genes in OSC remains unclear. We sought to construct a model based on mitochondrial genes for prognosis prediction, drug guidance and immune feature analysis of OSC. Methods Differentially expressed genes (DEGs) and mitochondrial-related DEGs (MRGs) were identified through the Cancer Genome Atlas (TCGA)-OV dataset. Consensus clustering algorithm was applied to classify OSC patients into distinct MRGs subtypes. Prognosis-related MRGs were screened to construct the prognosis-related Risk score model, which was verified using GSE26193 dataset and immunohistochemistry (IHC) score model based on staining intensity and extent scores of MRGs. A visualized nomogram was developed to predict 1-, 3- and 5-year overall survival (OS) and drug response. The correlation of MRGs subtypes with risk subgroups and the association of Risk score model with immune response and infiltration were also investigated. Results 341 MRGs were identified from TCGA-OV, and OSC patients could be mainly divided into two MRGs subtypes. A novel prognostic Risk score model based on 7-MRGs, including ACOT13 , ACSS3 , COA6 , HINT2 , MRPL14 , NDUFC2 and NDUFV2 , was developed and validated via GSE26193 dataset and IHC score model. Patients in the low-risk group had a significantly longer OS. The nomogram exhibited good prognostic assessment accuracy in both training and validation datasets. Drug sensitivity analysis indicated that cisplatin, paclitaxel and docetaxel were more sensitive in the low-risk group; VEGFR inhibitor Axitinib, and BRAF inhibitors Vemurafenib and SB590885 showed better sensitivity in the high-risk group; moreover, patients in the low-risk group could have better anti-PD-1 immunotherapy response. Patients in “cluster1” MRGs subtype had lower risk scores and better immunotherapy response scores than the “cluster2” subgroup. More significant infiltrated tumor killing cells (CD8 + T cells) and higher M1 / M2 macrophage ratio were in “cluster1” patients. Conclusions Our novel 7 MRGs-based Risk score model has huge prospects to evaluate the prognosis and guide drug treatment. The favorable prognosis associated with the low-risk group is closely related to better immune response and more significant anti-tumor cellular infiltration.

Zebrafish tumour xenograft models: a prognostic approach to epithelial ovarian cancer

Zebrafish Patient-Derived Xenograft System for Predicting Carboplatin Resistance and Metastasis of Ovarian Cancer

Zebrafish Avatars: Toward Functional Precision Medicine in Low-Grade Serous Ovarian Cancer

Construction of a mitochondria genes-based model for prognosis prediction, drug guidance and immune feature analysis in ovarian serous cystadenocarcinoma

Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases

Clinical Outcomes and Prognostic Factors of Patients with Epithelial Ovarian Cancer Subjected to First-Line Treatment: a Retrospective Study of 251 Cases

A Predictive Model for Initial Platinum-Based Chemotherapy Efficacy in Patients with Postoperative Epithelial Ovarian Cancer Using Tissue-Derived Small Extracellular Vesicles

Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research

Zebrafish patient-derived xenografts accurately and quickly reproduce treatment outcomes in non-small cell lung cancer patients

Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer

A Multiplex Biomarker Assay Improves the Prediction of Survival in Epithelial Ovarian Cancer

The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool For Ovarian Cancer Immunotherapy Research.

A predictive and prognostic model for surgical outcome and prognosis in ovarian cancer computed by clinico-pathological and serological parameters (CA125, HE4, mesothelin)

Development of a long term, ex vivo, patient-derived explant model of endometrial cancer

Integrated Proteomics and Scrna-Seq Analyses of Ovarian Cancer Reveal Molecular Subtype-Associated Cell Landscapes and Immunotherapy Targets

Patient-Derived Xenografts Are a Reliable Preclinical Model for the Personalized Treatment of Epithelial Ovarian Cancer

The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers

Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer.

An EMT-based Gene Signature Enhances the Clinical Understanding and Prognostic Prediction of Patients with Ovarian Cancers

Identification of a cancer associated fibroblasts-related index to predict prognosis and immune landscape in ovarian cancer

Fish Tales: the Use of Zebrafish Xenograft Human Cancer Cell Models.